Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.

This study found that physoxia improved hair follicle functions in co-cultures of dermal papilla cells and melanocytes by enhancing their biological activities and promoting hair growth and pigmentation.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

This article communicates that there is no fundamental difference between the author's previous position on the future of hair restoration and opposing viewpoints but reports no new findings.

This article discusses a previous study on female pattern hair loss and responds to comments by other researchers without presenting new findings.

This study found that antioxidant vitamin treatment improved the hair growth rate in patients with alopecia areata, regardless of the duration of their condition.

This article discusses expert responses to hair loss in women but reports no new research findings.

This study examined how different forms of dietary zinc affect the dimensions, weight, and zinc content of dog hair to evaluate coat condition.

This study examined how the form of dietary zinc affects the dimensions, weight, and zinc content of dog hair, which are considered indicators of coat condition.

Women's acne improvement with antibiotics is not linked to signs of high male hormones.

This study found a perfect correlation between laser Doppler velocimetry measurements of scalp blood perfusion after minoxidil application and sulfotransferase enzyme activity in hair follicles, indicating a potential non-invasive test to predict minoxidil response in female pattern hair loss.

This review discusses the roles of dermal white adipose tissue (dWAT) as an insulator, antibiotic, and regenerative tissue, highlighting its importance in systemic metabolism and immune function, but reports no new clinical results.

This review discusses the role of noncoding RNAs (ncRNAs) in radiation response and highlights their potential as biomarkers for assessing radiation damage, but reports no new clinical results.

This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.

This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.

Low m6Ascores in melanoma predict better survival and response to immunotherapy.

This review explores the shared pathogenesis of alopecia areata and vitiligo and compares treatment responses, noting that hair regrowth in alopecia areata occurs more rapidly than skin re-pigmentation in vitiligo, possibly due to differences in stem cell biology and treatment effects on melanocytes.

This study aimed to identify reliable predictors for the effectiveness of metformin therapy in weight loss and reduction of plasma androgen levels in PCOS women, highlighting the unpredictability of response to treatment.

This study found that alopecia areata patients who responded poorly to topical immunotherapy had impaired peripheral blood mononuclear cell responses to T-cell stimulants.

This study developed microfluidics-based 3D microtumors to model minimal residual disease in ovarian cancer, highlighting their alignment with patient-derived MRD and response to a fatty acid oxidation inhibitor.

Finasteride can help induce ovulation and lead to a healthy birth in some women.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

In this study, baseline neutrophil-to-lymphocyte ratio (NLR) was associated with predicting early trichoscopic response in patients undergoing PRP-based treatment for non-scarring alopecia.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.

In this study, researchers found that patients with severe alopecia areata who respond to baricitinib treatment within six months may improve clinically within a year, while those with very severe disease may require at least a year for evidence of treatment effect.

In this study, the researchers found that after initial hair regrowth with ritlecitinib in patients with severe alopecia areata, it took a median of 93 days to reach clinical trial-defined scalp hair regrowth, with those responding earlier showing faster progression to desired outcomes.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.